Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

@article{Hochhaus2000MolecularHI,
  title={Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.},
  author={Andreas Hochhaus and A. Reiter and Susanne Saussele and Anja Reichert and Michael Emig and Jaspal Singh Kaeda and Beate S Schultheis and U. Berger and Pat C A Shepherd and Nick Allan and Rȕdiger Hehlmann and John M. Goldman and N. C. Cross},
  journal={Blood},
  year={2000},
  volume={95 1},
  pages={62-6}
}
A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a complete response (CR) to treatment with interferon-alpha (IFN), defined as the disappearance of Philadelphia chromosome-positive metaphases. Currently it is unclear how long IFN treatment should be continued for such patients. We used a competitive reverse transcriptase-polymerase chain reaction (RT-PCR) to quantify levels of BCR-ABL transcripts in 297 peripheral blood specimens collected from 54 patients who… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 75 extracted citations

Similar Papers

Loading similar papers…